Compare RELL & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | CDXS |
|---|---|---|
| Founded | 1947 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Major Chemicals |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.6M | 141.8M |
| IPO Year | N/A | 2010 |
| Metric | RELL | CDXS |
|---|---|---|
| Price | $10.85 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 80.1K | ★ 792.6K |
| Earning Date | 01-07-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ 71.90 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $212,588,000.00 | $52,932,000.00 |
| Revenue This Year | $5.91 | $15.64 |
| Revenue Next Year | $13.64 | $5.23 |
| P/E Ratio | $195.14 | ★ N/A |
| Revenue Growth | ★ 4.74 | N/A |
| 52 Week Low | $7.57 | $1.52 |
| 52 Week High | $13.88 | $5.16 |
| Indicator | RELL | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 48.98 |
| Support Level | $10.43 | $1.61 |
| Resistance Level | $11.06 | $1.74 |
| Average True Range (ATR) | 0.43 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 54.85 | 32.14 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.